Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

4 Oct 2012

Abstract excerpt

BACKGROUND: Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. Discrepancies between these methods may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Breast Lesions and Carcinomas
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23035882
DOI: 10.1186/1755-8794-5-44

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular MarkersPMID 23035882Read ↗

Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor CharacteristicsSemantic proximity Read ↗

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor ExpressionSemantic proximity Read ↗

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.Semantic proximity Read ↗

Cross-Platform Reproducible Modeling of Breast Cancer Prognosis Using the Core-PAM50 Gene SignatureSemantic proximity Read ↗

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.Semantic proximity Read ↗

Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Semantic proximity Read ↗

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancerSemantic proximity Read ↗

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.Semantic proximity Read ↗

Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive reviewSemantic proximity Read ↗

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read ↗

Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.Semantic proximity Read ↗

Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER ConsortiumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.